Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

FDA approves Lilly diabetes drug

by Gina Vitale
May 20, 2022 | A version of this story appeared in Volume 100, Issue 18

 

The US Food and Drug Administration has approved Mounjaro (tirzepatide), a type 2 diabetes drug from Eli Lilly and Company. The single-molecule injectable is the first FDA-approved drug to target receptors for both GIP and GLP-1, which are hormones that regulate insulin secretion. Lilly is also developing tirzepatide as a weight loss drug. While tirzepatide is not currently intended for weight loss, people with diabetes in Phase 3 trials lost an average of about 5 kg with the 5 mg dose and about 11 kg with the 15 mg dose, Lilly says.

CORRECTION:

This story was updated on Feb. 28, 2023, to correct the amount of weight that people with diabetes lost in studies of tirzepatide and to correct the number of studies. They lost on average about 5 kg with the 5 mg dose and about 11 kg with the 15 mg dose, not 5–15 kg. And the results were from multiple Phase 3 trials, not one trial.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.